Incidental PET/CT Detection of Breast Cancer in a Patient with Negative Mammogram and Breast Sonogram  by Lee, Edward W. et al.
Radiology Case Reports
Volume 2, Issue 3, 2007
Citation: Lee EW, Grant JD, Mari C. Incidental PET/CT detection of breast cancer in a patient 
with negative mammogram and breast sonogram. Radiology Case Reports. [Online] 
2007;2:84.
Copyright: © Edward W. Lee, MD, PhD. This is an open-access article distributed under the 
terms of the Creative Commons Attribution-NonCommercial-NoDerivs 2.5 License, which 
permits reproduction and distribution, provided the original work is properly cited. Com-
mercial use and derivative works are not permitted.
Abbreviations: CT, computed tomography
Edward W. Lee, MD, PhD (Email: EdwardLee@mednet.ucla.edu), is in the Department of 
Radiology, UCLA Medical Center, Los Angeles, California, USA.
Jonathan D. Grant, BS (Email: jondgrant@ucla.edu), is at the David Geffen School of Medi-
cine at UCLA, Los Angeles, California, USA
Carina Mari, MD, PhD (Email: carina.mari@radiology.ucsf.edu), is in the Department of Radi-
ology, Division of Nuclear Medicine, University of California, San Francisco, California, USA
Published: August 13, 2007
DOI: 10.2484/rcr.v2i3.84 
RCR Radiology Case Reports | radiology.casereports.net 1 DOI: 10.2484/rcr.2007.v2i3.84
Introduction
Incidental PET/CT Detection of Breast Cancer in 
a Patient with Negative Mammogram and Breast 
Sonogram 
Edward W. Lee, MD, PhD, Jonathan D. Grant, BS, and Carina Mari, MD, PhD
We present the case of a 57-year-old woman with known Hodgkins lymphoma who presented with 
PET/CT findings of a breast mass and diseased axillary lymph node despite negative results from a 
recent routine mammogram and ultrasound. Needle biopsy of the mass and lymph node confirmed a 
diagnosis of infiltrating ductal carcinoma of the breast with nodal metastases.
Most breast cancers are clinically detected during a 
screening exam. To confirm, mammography and ultra-
sound are the main diagnostic imaging modalities used. 
However, these conventional methods have diagnostic 
limitations. The imaging modality PET/CT is used in 
various fields of medicine its role in the diagnosis of breast 
cancer is getting more attention. In this case report, we 
present a 57-year-old woman with known Hodgkins lym-
phoma who presented with PET/CT findings of a breast 
Figure 1. 57-year-old woman with incidentally discovered 
metastatic breast cancer. Axial 18F-FDG PET/CT scans show-
ing an intensely hypermetabolic focus (arrows, SUVmax of 
7.7) in the lower lateral quadrant of the breast, correspond-
ing to the primary tumor: A, uncorrected PET image; B, CT 
image; C, corrected PET image; and D, fused PET/CT image.
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patient compliance, relatively low cost, and low radia-
tion exposure, mammography is widely used as first-line 
diagnostic imaging for breast cancer along with clinical 
examination. Ultrasound is indicated when determining if 
the breast mass is malignant or benign.
However, these conventional methods have diagnos-
tic limitations. 20% of palpable breast cancers are not 
detectable with mammography [2] and it has been shown 
to have a low positive predictive value (ranges from 5 to 
40%) [3], especially in patients with implants or who have 
undergone prior treatment for breast cancer [4] To help 
overcome these deficiencies, imaging techniques such as 
MRI, PET, magnetic resonance mammography [5] and 
scintimammography [6] are receiving attention.
PET/CT is a metabolic imaging modality that provides 
accurate correlation of metabolic changes with anatomical 
localization, making it useful in tumor diagnosis, stag-
ing, and monitoring of treatment. This modality is highly 
utilized in oncology and neurology, but it is considered 
unsuitable as a primary diagnostic method for breast 
cancer because of high expense, limited availability, low 
spatial resolution and whole-body radiation exposure. The 
advantages of PET/CT, however, include sensitivities and 
Discussion
Breast cancer is the most common female cancer and 
the second leading cancer death in women, with a yearly 
mortality of approximately 43,000 [1]. Because of high 
A 57-year-old woman with a history of Hodgkins lym-
phoma, treated with whole body radiation and splenec-
tomy 33 years ago, presented with recurrent left pleural 
effusions for the past two years. The patient was referred to 
Nuclear Medicine at our institution for re-staging of her 
Hodgkins lymphoma.
A full-body PET/CT scan with intravenous injec-
tion of 13.3 mCi of 18F-fluorodeoxyglucose (FDG) 
was performed at a rate of 5 minutes/bed. An intensely 
hypermetabolic focus (SUVmax of 7.7) was incidentally 
found in the lower lateral quadrant of the breast (Fig 1A, 
1C and 1D), which corresponded to a 17 mm soft-tissue 
lesion found on CT scan (Fig 1B). An additional intensely 
hypermetabolic focus (SUVmax of 3.8) was noted in the 
left pectoral muscle region (Fig 2A, 2C and 2D), which 
corresponded to a 6 mm left interpectoral lymph node on 
CT scan (Fig 2B). Otherwise, PET and CT were normal. 
The patient stated that no palpable mass was detected 
during a routine clinical examination, and mammogram 
and ultrasound four months before at an outside hospital 
was interpreted as negative for any breast mass.
A fine needle aspiration of the breast mass was per-
formed. Histological analysis of the breast mass showed at 
least intermediate-grade infiltrating ductal carcinoma. Im-
munohistochemistry showed the mass to be estrogen and 
progesterone receptor negative, Her2neu gene negative but 
KI-67 positive. A core needle biopsy of the interpectoral 
lymph node showed adenocarcinoma with breast origin, 
cytologically similar to the breast mass biopsy.
Due to an unstable cardiac condition, the patient was 
unable to undergo immediate treatment for her metastatic 
breast cancer. Four months later, a repeat PET/CT scan 
performed in our clinic showed essentially no change in 
mass/lymph node size or metabolic activities from the 
previous scan.
Case Report
Figure 2. Axial 18F-FDG PET/CT scans showing an intensely 
hypermetabolic focus (arrows, SUVmax of 3.8) in the left 
pectoral muscle, corresponding to a nodal metastasis: A, 
uncorrected PET image; B, CT image; C, corrected PET image; 
and D, fused PET/CT image.
mass and diseased axillary lymph node despite negative 
results from a recent routine mammogram and ultrasound. 
Needle biopsy of the mass and lymph node confirmed a 
diagnosis of infiltrating ductal carcinoma of the breast with 
nodal metastases.
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